FGF19 and FGF21: In NASH we trust
Objective: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. Methods: We performed a detailed analyses of published preclinical and clinical data to o...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | Molecular Metabolism |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221287782030226X |
| _version_ | 1818849552365518848 |
|---|---|
| author | Saswata Talukdar Alexei Kharitonenkov |
| author_facet | Saswata Talukdar Alexei Kharitonenkov |
| author_sort | Saswata Talukdar |
| collection | DOAJ |
| description | Objective: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. Methods: We performed a detailed analyses of published preclinical and clinical data to offer insights into the mechanism of action, as well as PK/PD and efficacy data of the clinical assets. Results: Scouring the literature, we offer mechanistic insights from preclinical data using rodents and non-human primates and pharmacodynamic data from clinical studies. Conclusion: The basic and applied science around endocrine FGFs has evolved exponentially over the years with FGF19 and FGF21 analogs are now entering Phase 3 clinical research. |
| first_indexed | 2024-12-19T06:35:03Z |
| format | Article |
| id | doaj.art-e2aa42684f574b7a82ad4c4a8c6eeade |
| institution | Directory Open Access Journal |
| issn | 2212-8778 |
| language | English |
| last_indexed | 2024-12-19T06:35:03Z |
| publishDate | 2021-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Metabolism |
| spelling | doaj.art-e2aa42684f574b7a82ad4c4a8c6eeade2022-12-21T20:32:15ZengElsevierMolecular Metabolism2212-87782021-04-0146101152FGF19 and FGF21: In NASH we trustSaswata Talukdar0Alexei Kharitonenkov1Merck & Co., Inc., 213 East Grand Avenue, South San Francisco, CA, 94080, United States; Corresponding author.AK Biotechnologies, LLC 3812 Verdure Lane, Zionsville, IN, 46077, United States; Corresponding author.Objective: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. Methods: We performed a detailed analyses of published preclinical and clinical data to offer insights into the mechanism of action, as well as PK/PD and efficacy data of the clinical assets. Results: Scouring the literature, we offer mechanistic insights from preclinical data using rodents and non-human primates and pharmacodynamic data from clinical studies. Conclusion: The basic and applied science around endocrine FGFs has evolved exponentially over the years with FGF19 and FGF21 analogs are now entering Phase 3 clinical research.http://www.sciencedirect.com/science/article/pii/S221287782030226XFGF21FGF19NASHMetabolismDrug developmentClinical trials |
| spellingShingle | Saswata Talukdar Alexei Kharitonenkov FGF19 and FGF21: In NASH we trust Molecular Metabolism FGF21 FGF19 NASH Metabolism Drug development Clinical trials |
| title | FGF19 and FGF21: In NASH we trust |
| title_full | FGF19 and FGF21: In NASH we trust |
| title_fullStr | FGF19 and FGF21: In NASH we trust |
| title_full_unstemmed | FGF19 and FGF21: In NASH we trust |
| title_short | FGF19 and FGF21: In NASH we trust |
| title_sort | fgf19 and fgf21 in nash we trust |
| topic | FGF21 FGF19 NASH Metabolism Drug development Clinical trials |
| url | http://www.sciencedirect.com/science/article/pii/S221287782030226X |
| work_keys_str_mv | AT saswatatalukdar fgf19andfgf21innashwetrust AT alexeikharitonenkov fgf19andfgf21innashwetrust |